



## **GLOSSARY**





## Glossary

### Adjuvant chemotherapy

Adjuvant chemotherapy (postoperative treatment) is used to eradicate any microscopic non-detectable cancer cells when there is little evidence of cancer presence but there is a risk of circulating microscopic cancer cells that could lead to recurrence.

### Axillary dissection

A surgical procedure to remove the lymph nodes in the armpit (axillary nodes) hidden under the pectoral major and minor muscles. It is performed when there is evidence of cancerous cells in lymph nodes with palpation or imaging, or as sentinel lymph nodes.

### Bilateral breast cancer

Bilateral breast cancer is cancer occurring in both breasts at the same time or within six months of each other (synchronous), or at different times at least six months apart (metachronous).

### Biological subtype

Breast cancer is not considered to be a single disease. It can be further classified into several biological subtypes. These subtypes are determined by immunohistochemical staining of several biological markers (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67). By combining these biological markers in the primary tumour rather than assessing them individually, further prognostic and predictive information can be gained. The biological subtypes of breast cancers include luminal A (ER+ and/or PR+, HER2- and Ki-67 low), luminal B (HER2-negative) (ER+ and/or PR+, HER2-, and Ki-67 high), luminal B (HER2-positive) (ER+ and/or PR+, HER2+, and any Ki-67), HER2-positive (ER-, PR-, HER2+, and any Ki-67) and triple negative (ER-, PR-, HER2-, and any Ki-67)<sup>32</sup>.

### Breast conserving surgery

This could be lumpectomy, wide local excision, partial mastectomy or segmentectomy. It is the surgical removal of a cancerous breast lump with a rim of non-cancerous tissue around the lump, without removing the entire breast.

### Breast reconstruction surgery

This refers to a surgical treatment that rebuilds the breast contour after mastectomy. A breast implant of the woman's own tissue provides the contour. If desired, the nipple and areola may also be preserved or recreated. Reconstruction can usually be done at the time of mastectomy or any time later.

### Breast surgery

Surgery for breast cancer is a local therapy to remove the breast tumour.

## Cancer Staging

According to the latest AJCC Cancer Staging 2010<sup>31</sup>, breast cancer can be classified into different stages as shown in the following table:

Stage	Tumour	Node	Metastasis
0	Tis	N0	M0
IA	T1*	N0	M0
IB	T0	N1mi	M0
	T1*	N1mi	M0
IIA	T0	N1**	M0
	T1*	N1**	M0
	T2	N0	M0
IIB	T2	N1	M0
	T3	N0	M0
IIIA	T0	N2	M0
	T1*	N2	M0
	T2	N2	M0
	T3	N1	M0
	T3	N2	M0
IIIB	T4	N0	M0
	T4	N1	M0
	T4	N2	M0
IIIC	Any T	N3	M0
IV	Any T	Any N	M1

T0: no tumour; Tis: carcinoma in situ; T1: tumour size  $\leq$  20mm; T2: 20mm < tumour size  $\leq$  50mm; T3: tumour size > 50mm; T4: any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)

N0: no positive nodes; N1mi: >0.2-2.0 mm or more than 200 cells; N1: 1-3 positive nodes; N2: 4-9 positive nodes; N3:  $\geq$  10 nodes

M0: no metastasis; M1: evidence of metastasis

\* T1 includes T1mi

\*\* T0 and T1 tumour with nodal micrometastases only are excluded from Stage IIA and are classified as Stage IB.

## Cancer specific death

A death with the underlying cause indicated as cancer. People with cancer who die of other causes are not counted in the death statistics of this publication.

## Chemotherapy

It is a treatment that uses one or more cytotoxic drugs to destroy cancer cells. Chemotherapy is often used in addition to surgery or radiation to treat cancer when metastasis (spread) is proven or suspected, when the cancer has come back (recurred), or when there is a strong likelihood that the cancer could recur.

## Distant recurrence

Cancer that occurs in organs or tissues distant from the original site or regional lymph nodes, such as the lungs, liver, bone marrow, or brain.

## Endocrine therapy

Treatment with hormonal drugs that interfere with hormone production or hormone action, or surgical removal of hormone-producing glands to kill cancer cells or cause programmed cell death (apoptosis).

## Estrogen receptor positive

This refers to the status of cancer cells with receptor proteins that bind the hormone estrogen. Cancer cells that are estrogen receptor positive need estrogen to grow, and may stop growing or die when treated with substances that block the binding with estrogen.

## Human epidermal growth factor receptor 2 (HER2) positive

In HER2 positive breast cancer, the cancer cells have an abnormally large number of HER2 genes per cell. When this happens, excessive HER2 protein appears on the surface of these cancer cells. This is called HER2 protein over-expression. Excessive HER2 protein is thought to cause cancer cells to grow and divide more quickly. This is why HER2 positive breast cancer is considered aggressive.



### **In situ breast cancer**

This term refers to early stage breast cancer, when it is confined to the layer of cells where it began. In breast cancer, in situ means that the cancer cells remain confined to ducts (ductal carcinoma in situ). They have not grown into deeper tissues in the breast or spread to other organs in the body, and are sometimes referred to as non-invasive or pre-invasive breast cancers.

### **Invasive breast cancer**

An invasive cancer is one that has already grown beyond the outer lining of myoepithelial cells or basement membrane where it started, for example breast ducts or lobules (as opposed to carcinoma in situ). Most breast cancers are invasive carcinomas.

### **Ki-67 proliferation index**

Ki-67 protein is a cellular marker for proliferation which is present at low levels in quiescent cells but is increased in proliferating cells. Ki-67 proliferation index, referring to the percent tumour cells staining positive as measured by immunohistochemical (IHC) staining, is a specific nuclear marker for cell proliferation. High levels of Ki-67 indicate an aggressive tumour. Currently, an index higher than 14% is regarded as high Ki-67 proliferation index.

### **Latissimus dorsi flap (LD flap)**

This refers to a method of breast reconstruction that rotates the fan-shaped flat muscle of the back to the chest area.

### **Proliferative lesions with atypia and precancerous breast lesion**

Proliferative lesions with atypia include atypical ductal hyperplasia and atypical lobular hyperplasia. In these conditions, there is an overgrowth of cells in the ducts or lobules of the breast tissue, with some of the cells no longer appearing normal. These conditions increase the risk of breast cancer. Lobular carcinoma in situ (LCIS) is considered a precancerous lesion, a risk factor for developing invasive breast cancer in future, but is not classified as breast cancer.

### **Locoregional recurrence**

Locoregional recurrence occurs when cancer returns after treatment, and occurs at the same site as the original cancer or in the lymph nodes near the site of origin.

### **Mastectomy**

A mastectomy is the surgical removal of the entire breast. It is usually used to treat serious breast disease, such as breast cancer.

### **Metastasis**

The term metastasis is used to describe a disease that has recurred at another location in the body.

### **Mortality**

Mortality is the incidence of death in a population.

### **Multicentricity**

Breast cancer occurring in multiple quadrants of a breast.

### **Multifocality**

Multifocality in breast cancer is defined as the presence of two or more tumour foci within a single quadrant of the breast with two or more foci 5mm apart in the same breast quadrant.

### **Necrosis**

A term used to describe the death of cellular tissue. Necrosis within a cancerous tumour may indicate that the tumour is growing so rapidly that blood vessels are not able to multiply fast enough to nourish some of the cancer cells. Necrosis usually indicates that the tumour is very aggressive and can spread quickly.

### **Neoadjuvant chemotherapy**

In neoadjuvant chemotherapy (preoperative treatment), initial chemotherapy is designed to shrink the primary tumour, thereby rendering local therapy (surgery or radiotherapy) less destructive or more effective.

### **Progesterone receptor positive**

The hormone progesterone will bind to protein in cells. Cancer cells that are progesterone receptor positive need progesterone to grow and will usually stop growing when endocrine therapy drugs block progesterone from binding.

### **Radiation therapy**

Radiation therapy is the use of radiation to destroy cancer cells. External sources of radiation used include linear accelerators, cobalt, and betatrons. This type of treatment may be used to reduce the size of a cancer before surgery, or to destroy any remaining cancer cells after surgery.

### **Risk factors**

Risk factors are associated with an increased probability of a specified outcome, for example, the occurrence of a disease. Risk factors are not necessarily the cause of a disease.

### **Sentinel node biopsy**

It is a surgical procedure to remove the first few nodes receiving lymphatic drainage from the breast in clinically node-negative cancers. This is to determine if breast cancer has spread to the armpit (axillary) lymph node basin.

### **Survival time**

The time from initial diagnosis until the occurrence of death.

### **Targeted therapy**

A type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumour growth.

### **Time to recurrence**

The time from initial diagnosis until the occurrence of recurrence.

### **Transverse rectus abdominus muscle flap (TRAM flap)**

A method of breast reconstruction in which tissue from the lower abdominal wall receiving its blood supply from the rectus abdominus muscle is used. The tissues from this area are moved up to the chest to create a breast mound; usually an implant is not required. Moving muscles and tissues from the lower abdomen to the chest results in flattening of the lower abdomen.

### **Triple negative breast cancer**


This term is used to describe breast cancers (usually invasive ductal carcinomas) in which the cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces.





## **LIST OF TABLES AND FIGURES**

---




## LIST OF TABLES

	Page	
Table I	Number of patients whose data were used for analysis in different chapters of this report	12
Table II	The sources of patient consent in this and previous reports	12
Table 1.1	Dietary habits, exercise habits, and stress level at the time of diagnosis (N=14,035)	38
Table 1.2	Body mass index at the time of diagnosis (N=14,035)	38
Table 1.3	Family history of our patient cohort at the time of diagnosis (N=14,035)	38
Table 1.4	Personal histories of tumours of our patient cohort at the time of diagnosis (N=14,035)	39
Table 1.5	Types of malignant tumours reported by our patient cohort (N=271)	39
Table 1.6	History of breast disease at the time of diagnosis	40
Table 1.7	Early menarche, late menopause, and reproductive history at the time of diagnosis	41
Table 1.8	Number of live births reported by our patient cohort (N=10,725)	41
Table 1.9	Use of hormonal contraceptives at the time of diagnosis (N=14,035)	42
Table 1.10	Use of hormonal replacement therapy (in our post-menopausal patients in the cohort) at the time of cancer diagnosis (N=6,848)	42
Table 1.11	The ten most common risk factors in our patient cohort (N=14,035)	42
Table 1.12	Breast screening habits of our patient cohort by age group	44
Table 1.13	Breast screening habits of our patient cohort by patients' residential district	45
Table 2.1	Method of first breast cancer detection by types of medical service received for cancer diagnosis and treatment (N=13,053)	51
Table 2.2	Method of first breast cancer detection by type of cancer (N=12,668)	52
Table 2.3	Method of first breast cancer detection by cancer stage (N=12,511)	52
Table 2.4	Time interval between the onset of symptoms and first medical consultation for our patients who self-detected* their cancers (N=2,984)	53
Table 2.5	Time interval between the onset of symptoms and first medical consultation for our patients who self-detected* their cancers by types of medical service received (N=2,984)	53
Table 2.6	Time interval between the onset of symptoms and first medical consultation for our patients who self-detected* their cancers by cancer stage at diagnosis (N=2,704)	54
Table 2.7	Sensitivity and diagnostic results of breast imaging tests (N=14,064)	55
Table 2.8	Mammographic findings of patients in our cohort who were diagnosed through mammography (N=9,215)	56



	Page
Table 2.9	Mammographic density of breasts of our patients who were diagnosed through mammography by age group (N=6,388) 56
Table 2.10	Sensitivity and diagnostic results of breast tissue biopsies (N=14,064) 57
Table 2.11	Cancer staging in 10,548 invasive breast cancer patients 57
Table 2.12	The use of PET scan as a form of staging methods by cancer stage (N=7,969) 58
Table 2.13	Histological type, grading, multifocality and multicentricity of invasive breast cancers (N=11,203) 60
Table 2.14	Biological characteristics of invasive breast cancers (N=11,203) 61
Table 2.15	Biological subtypes of invasive tumours by cancer stage (N=10,299) 61
Table 2.16	Histological type, grading, multifocality and multicentricity of in situ breast cancers (N=1,761) 62
Table 2.17	Biological characteristics of in situ breast cancers (N=1,761) 62
Table 2.18	Types of surgical operations in our patient cohort (N=14,064) 63
Table 2.19	Use of chemotherapy by age group and cancer stage at diagnosis (N=11,334) 67
Table 2.20	Irradiated regions among our patients with different types of surgery (N=5,913) 70
Table 2.21	Number of treatment combinations received by patients by cancer stages (N=13,409) 72
Table 2.22	Follow-up of 12,573 patients 73
Table 2.23	Number of cases with locoregional recurrence by type of surgery and cancer stage 74
Table 2.24	Sites involved in locoregional recurrence in our patients (N=494) 74
Table 2.25	Organs involved in distant recurrence (N=485) 75
Table 2.26	Proportions of our invasive breast cancer patients with locoregional and distant recurrence by cancer stage 75
Table 2.27	Characteristics of breast cancer-specific deaths (N=119) 76
Table 3.1	The five most common forms of discomfort after surgery (N=12,313) 79
Table 3.2	The five most common forms of discomfort after chemotherapy (N=7,513) 80
Table 3.3	The five most common forms of discomfort after radiotherapy (N=7,424) 81
Table 3.4	The five most common forms of discomfort after endocrine therapy (N=7,735) 81
Table 3.5	The five most common forms of discomfort after targeted therapy (N=1,008) 82
Table 3.6	Psychosocial impacts of breast cancer on our patients 83
Table 3.7	Psychosocial adjustments and coping strategies for survivorship 84



## LIST OF FIGURES

	Page
Figure I	8
Figure 1.1	35
Figure 1.2	35
Figure 1.3	36
Figure 1.4	36
Figure 1.5	36
Figure 1.6	36
Figure 1.7	36
Figure 1.8	43
Figure 2.1	51
Figure 2.2	52
Figure 2.3	54
Figure 2.4	54
Figure 2.5	56
Figure 2.6	58
Figure 2.7	58
Figure 2.8	59
Figure 2.9	59
Figure 2.10	64
Figure 2.11	64
Figure 2.12	64
Figure 2.13	64
Figure 2.14	65
Figure 2.15	65
Figure 2.16	65
Figure 2.17	66
Figure 2.18	66
Figure 2.19	68

	Page	
Figure 2.20	The use of radiotherapy in our patients receiving breast-conserving surgery at different cancer stages (N=4,648)	69
Figure 2.21	The use of radiotherapy in our patients receiving mastectomy at different cancer stages (N=8,388)	69
Figure 2.22	Proportions of our patients who received endocrine therapy by cancer stage (N=13,224)	70
Figure 2.23	Forms of endocrine therapy used in our patient cohort by age group (N=8,672)	71
Figure 2.24	Targeted therapy rate in the HER2 positive patients by cancer stage in our cohort (N=2,050)	71
Figure 2.25	Type of drugs used for targeted therapy in our patient cohort (N=930)	71
Figure 2.26	Type of complementary and alternative therapies used in 5,602 patients	72
Figure 3.1	Level of physical discomfort after surgical operations (N=12,313)	79
Figure 3.2	Level of physical discomfort by type of surgery (N=12,255)	79
Figure 3.3	Level of physical discomfort after chemotherapy (N=7,513)	80
Figure 3.4	Level of physical discomfort after radiotherapy (N=7,424)	80
Figure 3.5	Level of physical discomfort after radiotherapy by irradiated regions (N=7,424)	81
Figure 3.6	Level of physical discomfort after endocrine therapy (N=7,735)	81
Figure 3.7	Level of physical discomfort after targeted therapy (N=1,008)	82
Figure 3.8	Level of physical discomfort after complementary and alternative therapies (N=3,156)	82
Figure 3.9	Change in outlook on life by age group (N=11,740)	83
Figure 3.10	Change in self-image by age group (N=11,744)	84
Figure 3.11	Level of worry about recurrence by age group (N=11,730)	84